| URL | https://firstwordpharma.com/story/7172653 |
| Source | firstwordpharma.com |
| Date Published | 04/06/2026 |
| Company/Division name | SpectronRx |
| Parent company | SpectronRx |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2026 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 85 |
| City reshored to: | Indianapolis |
| State(s) reshored to: | IN |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | radiopharmaceuticals |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption |